PLRZHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 11 Sept 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Polyrizon Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Value (9): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PLRZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLRZ appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Polyrizon Ltd. returned +41.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 66% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 29% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Polyrizon Ltd. has a market value of $26.2M and an enterprise value of $5.6M.
Polyrizon Ltd. employs 2 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Polyrizon Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Polyrizon Ltd. announced the closing of a $4.0 million registered direct offering and private placement. The company, headquartered in Raanana, Israel, made the announcement on September 4, 2026.
Why it matters — The closing of this offering indicates the company has secured new capital, which PLRZ watchers would track as a liquidity and financing event.
Polyrizon Ltd. announced it has entered into definitive agreements with a single institutional investor for a registered direct offering of its Ordinary Shares and pre-funded warrants, along with a concurrent private placement of pre-funded and investor warrants. Aggregate gross proceeds from both transactions are expected to be approximately $4.0 million.
Why it matters — This capital raise provides Polyrizon with funding for its development-stage intranasal hydrogel programs.
Polyrizon announced it has completed contracting with the fourth and fifth clinical sites participating in its U.S. clinical study of NASARIX™ Allergy Blocker (PL-14), thereby completing all five site contracts for the first-in-human allergy study.
Why it matters — This milestone means all required U.S. clinical sites for the NASARIX first-in-human allergy study are now contracted, moving the development-stage biotech closer to initiating its trial.
Polyrizon announced it has completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker (PL-14) study and is advancing toward enrollment of 120 patients. The company is a development-stage biotech specializing in intranasal hydrogels.
Why it matters — Completing the clinical site network moves Polyrizon closer to patient enrollment in its NASARIX™ study, a key development milestone for the company's pipeline.
As at 11 Sept 2026, Polyrizon Ltd. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
No analyst covering Polyrizon Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRZ are extrapolating price history, which says nothing about the business.
Polyrizon Ltd. returned +41.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Polyrizon Ltd. is an Israel-based biotechnology company focused on developing innovative intranasal protective products.
The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement". Polyrizon Ltd. announced the closing of a $4.0 million registered direct offering and private placement. The company, headquartered in Raanana, Israel, made the announcement on September 4, 2026.
Polyrizon Ltd. is an Israel-based biotechnology company focused on developing innovative intranasal protective products. The company specializes in medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity, designed to help prevent viruses, allergens, and other airborne particles from contacting nasal tissue. Its proprietary Capture and Contain technology is intended to create a temporary shield in the nose, while its Trap and Target platform supports intranasal delivery of active pharmaceutical ingredients. Polyrizon also develops product candidates aimed at nasal allergy blocking and influenza protection. In addition to preventative intranasal solutions, the company works on improving bioadhesion and retention characteristics for drug delivery applications. Polyrizon Ltd. serves the healthcare and biotechnology markets through research, development, and commercialization of nasal-care technologies.
CEO Mr. Tomer Izraeli · 2 employees · Israel · https://www.polyrizon-biotech.com
